Inhibitors of signal transduction protein kinases as targets for cancer therapy.

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Biotechnology Annual Review

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/S1387-2656(06)12006-2PMID 17045195
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Protein kinase C (PKC) family in cancer progression.

  2006cited by this paper
• Treatment of high-grade astrocytic tumors with the humanized anti-EGF-R antibody h-R3 and radiotherapy

  2005cited by this paper
• Structural Bioinformatics-Based Design of Selective, Irreversible Kinase Inhibitors

  2005cited by this paper
• A phase II Trial of EMD72000 (matuzumab), a humanized anti-EGFR monoclonal antibody in subjects with heavily treated and platinum-resistant advanced Mullerian malignancies

  2005cited by this paper
• Encouraging Results for Second-Generation Antiangiogenesis Drugs

  2005cited by this paper
• mTOR-targeted therapy of cancer with rapamycin derivatives.

  2005cited by this paper
• FLT-3: a new focus in the understanding of acute leukemia.

  2005cited by this paper
• Mechanisms of BCR–ABL in the pathogenesis of chronic myelogenous leukaemia

  2005cited by this paper
• A phase II study of AP23573 (an mTOR inhibitor) in patients (pts) with advanced sarcomas

  2005cited by this paper
• Randomized phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43–9006) in patients with advanced renal cell carcinoma (RCC)

  2005cited by this paper
• Phase I/II trial of gefitinib and RAD001 (everolimus) in patients (pts) with advanced non-small cell lung cancer (NSCLC)

  2005cited by this paper
• Enhanced Phosphorylation of Nbs1, a Member of the DNA Repair/Checkpoint Activation Complex Rad50/Mre11/Nbs1, Prolongs Cell Cycle S Phase and Contributes to Drug Resistance in BCR/ABL-Positive Leukemias.

  2005cited by this paper
• A phase 2 clinical trial of AP23573, an mTOR inhibitor, in patients with relapsed or refractory hematologic malignancies

  2005cited by this paper
• PTK 787/ZK 222584, a Tyrosine Kinase Inhibitor of all Known VEGF Receptors, Represses Tumor Growth with High Efficacy

  2005cited by this paper
• Activation of AKT kinases in cancer: implications for therapeutic targeting.

  2005cited by this paper
• Hsp90 inhibitor geldanamycin and its derivatives as novel cancer chemotherapeutic agents.

  2005cited by this paper
• Recent results and ongoing trials with panitumumab (ABX-EGF), a fully human anti-epidermal growth factor receptor antibody, in metastatic colorectal cancer.

  2005cited by this paper
• The activation of Akt/PKB signaling pathway and cell survival

  2005cited by this paper
• Phase 1 Clinical and Pharmacokinetics Evaluation of Oral CI-1033 in Patients with Refractory Cancer

  2005cited by this paper
• Preliminary phase II safety evaluation of ZD6474, in combination with carboplatin and paclitaxel, as 1st-line treatment in patients with NSCLC

  2005cited by this paper
• Phase I study of BAY 43-9006 (sorafenib), a Raf kinase and VEGFR inhibitor, combined with irinotecan (CPT-11) in advanced solid tumors

  2005cited by this paper
• Results from phase II trial of enzastaurin (LY317615) in patients with recurrent high grade gliomas

  2005cited by this paper
• A phase I/II trial of the oral mTOR-inhibitor everolimus (E) and imatinib mesylate (IM) in patients (pts) with gastrointestinal stromal tumor (GIST) refractory to IM: Study update

  2005cited by this paper
• A phase II, randomized trial using the small molecule tyrosine kinase inhibitor lapatinib as a first-line treatment in patients with FISH positive advanced or metastatic breast cancer

  2005cited by this paper
• A phase II study of BAY 43–9006 in patients with recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC) and nasopharyngeal cancer (NPC)

  2005cited by this paper
• Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours

  2005cited by this paper
• CpG ISLAND METHYLATION PATTERNS IN VARIOUS HISTOTYPES OF ENDOMETRIAL CANCER: 0011

  2005cited by this paper
• Phase I clinical evaluation of AZD2171, a highly potent VEGF receptor tyrosine kinase inhibitor, in patients with advanced tumors

  2005cited by this paper
• An expanding role for mTOR in cancer.

  2005cited by this paper
• A Multicenter Phase II Trial of ZD6474, a Vascular Endothelial Growth Factor Receptor-2 and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients with Previously Treated Metastatic Breast Cancer

  2005cited by this paper
• Efficacy and toxicity of the antisense oligonucleotide aprinocarsen directed against protein kinase C-alpha delivered as a 21-day continuous intravenous infusion in patients with recurrent high-grade astrocytomas.

  2005cited by this paper
• Signal transduction pathways in cancer development and as targets for cancer prevention.

  2005cited by this paper
• Tyrosine kinases as targets for cancer therapy.

  2005cited by this paper
• Lessons in Rational Drug Design for Protein Kinases

  2005cited by this paper
• Technology evaluation: nimotuzumab, the Center of Molecular Immunology/YM BioSciences/Oncoscience.

  2005cited by this paper
• Overview of monoclonal antibodies in cancer therapy: present and promise.

  2005cited by this paper
• Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3.

  2005cited by this paper
• Tyrosine kinase inhibitors and the dawn of molecular cancer therapeutics.

  2005cited by this paper
• Raf Kinase Inhibitors in Oncology

  2005cited by this paper
• A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance.

  2005cited by this paper
• A phase I clinical trial of a ribozyme-based angiogenesis inhibitor targeting vascular endothelial growth factor receptor-1 for patients with refractory solid tumors

  2005cited by this paper
• Phosphorylation and Regulation of Akt/PKB by the Rictor-mTOR Complex

  2005cited by this paper
• A phase I study of BAY 43–9006, a dual inhibitor of Raf and VEGFR kinases, in Japanese patients with solid cancers

  2005cited by this paper
• Phase I trial of BAY 43-9006 (sorafenib) combined with dacarbazine (DTIC) in metastatic melanoma patients

  2005cited by this paper
• Nanobodies as novel agents for cancer therapy

  2005cited by this paper
• BMS-354825: a novel drug with potential for the treatment of imatinib-resistant chronic myeloid leukaemia

  2005cited by this paper
• Bevacizumab--current status and future directions.

  2005cited by this paper
• Phase I study of LErafAON-ETU, an easy-to-use formulation of liiposome entrapped c-raf antisense oligonucleotide, in advanced cancer patients

  2005cited by this paper
• A phase II study of BAY 43–9006 in patients with androgen-independent prostate cancer (AIPC) with proteomic profiling

  2005cited by this paper
• Role of Tyrosine Kinase Inhibitors in Cancer Therapy

  2005cited by this paper
• Epidermal growth factor receptor inhibitors in the treatment of non-small-cell lung cancer.

  2005cited by this paper
• Final findings from a phase II, placebo-controlled, randomized discontinuation trial (RDT) of sorafenib (BAY 43–9006) in patients with advanced renal cell carcinoma (RCC)

  2005cited by this paper
• Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412.

  2005cited by this paper
• Safety and pharmacokinetic study of RPI.4610 (ANGIOZYME), an anti-VEGFR-1 ribozyme, in combination with carboplatin and paclitaxel in patients with advanced solid tumors

  2005cited by this paper
• AMN107: tightening the grip of imatinib.

  2005cited by this paper
• Colorectal cancer: Mutations in a signalling pathway

  2005cited by this paper
• Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer.

  2005cited by this paper
• Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma.

  2005cited by this paper
• Mutational analysis of the ARAF gene in human cancers

  2005cited by this paper
• A phase I trial of aprinocarsen (ISIS 3521/LY900003), an antisense inhibitor of protein kinase C-α administered as a 24-hour weekly infusion schedule in patients with advanced cancer

  2005cited by this paper
• Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation.

  2005cited by this paper
• Integrin-linked kinase: a cancer therapeutic target unique among its ILK

  2005cited by this paper
• A phase I study of BAY 43-9006 and gefitinib in patients with refractory or recurrent non-small-cell lung cancer (NSCLC)

  2005cited by this paper
• Structural basis for inhibition of the epidermal growth factor receptor by cetuximab.

  2005cited by this paper
• A small molecule–kinase interaction map for clinical kinase inhibitors

  2005cited by this paper
• Phase I trial of the cyclin-dependent kinase inhibitor and protein kinase C inhibitor 7-hydroxystaurosporine in combination with Fluorouracil in patients with advanced solid tumors.

  2005cited by this paper
• Pharmacodynamic analysis of target inhibition and endothelial cell death in tumors treated with the vascular endothelial growth factor receptor antagonists SU5416 or SU6668.

  2005cited by this paper
• Safety and Pharmacokinetics of the Dual Action Raf Kinase and Vascular Endothelial Growth Factor Receptor Inhibitor, BAY 43-9006, in Patients with Advanced, Refractory Solid Tumors

  2005cited by this paper
• The biology of vascular endothelial growth factors.

  2005cited by this paper
• Soluble markers for the assessment of biological activity with PTK787/ZK 222584 (PTK/ZK), a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor in patients with advanced colorectal cancer from two phase I trials.

  2005cited by this paper
• Inhibition of integrin-linked kinase by a selective small molecule inhibitor, QLT0254, inhibits the PI3K/PKB/mTOR, Stat3, and FKHR pathways and tumor growth, and enhances gemcitabine-induced apoptosis in human orthotopic primary pancreatic cancer xenografts.

  2005cited by this paper
• The serine/threonine protein kinase, p90 ribosomal S6 kinase, is an important regulator of prostate cancer cell proliferation.

  2005cited by this paper
• Optimization of 6,7-disubstituted-4-(arylamino)quinoline-3-carbonitriles as orally active, irreversible inhibitors of human epidermal growth factor receptor-2 kinase activity.

  2005cited by this paper
• A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease.

  2005cited by this paper
• The Cyclin-Dependent Kinase Inhibitor UCN-01 Plus Cisplatin in Advanced Solid Tumors: A California Cancer Consortium Phase I Pharmacokinetic and Molecular Correlative Trial

  2005cited by this paper
• Inhibition of ILK in PTEN-mutant human glioblastomas inhibits PKB/Akt activation, induces apoptosis, and delays tumor growth

  2005cited by this paper
• Second nature: Biological functions of the Raf‐1 “kinase”

  2005cited by this paper
• Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study.

  2005cited by this paper
• Melanoma genetics and the development of rational therapeutics.

  2005cited by this paper
• A phase I and pharmacokinetic study of short infusions of UCN-01 in patients with refractory solid tumors.

  2005cited by this paper
• Clinical trials of intracellular signal transductions inhibitors for breast cancer--a strategy to overcome endocrine resistance.

  2005cited by this paper
• The broad-range cyclin-dependent kinase inhibitor UCN-01 induces apoptosis in colon carcinoma cells through transcriptional suppression of the Bcl-xL protein

  2005cited by this paper
• A screen of the complete protein kinase gene family identifies diverse patterns of somatic mutations in human breast cancer

  2005cited by this paper
• Cancer. Encouraging results for second-generation antiangiogenesis drugs.

  2005cited by this paper
• A phase I safety and dose escalation trial of docetaxel combined with GEM®231, a second generation antisense oligonucleotide targeting protein kinase A R1α in patients with advanced solid cancers

  2005cited by this paper
• ZD6474 – clinical experience to date

  2005cited by this paper
• Recent progress in targeting the Raf/MEK/ERK pathway with inhibitors in cancer drug discovery.

  2005cited by this paper
• The MAPK signalling pathways and colorectal cancer.

  2005cited by this paper
• N997B: Phase II trial of CCI-779 in recurrent glioblastoma multiforme (GBM): Updated results and correlative laboratory analysis

  2005cited by this paper
• Localized effects of cAMP mediated by distinct routes of protein kinase A.

  2004cited by this paper
• Antitumor Activity of HKI-272, an Orally Active, Irreversible Inhibitor of the HER-2 Tyrosine Kinase

  2004cited by this paper
• Recent Advances in Stress Signaling in Cancer

  2004cited by this paper
• Synergistic effect of SU11248 with cytarabine or daunorubicin on FLT3 ITD-positive leukemic cells.

  2004cited by this paper
• Bevacizumab in the treatment of breast cancer: rationale and current data.

  2004cited by this paper
• Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition

  2004cited by this paper
• Kinase Inhibition with BAY 43–9006 in Renal Cell Carcinoma

  2004cited by this paper
• A Phase I Trial of Perifosine (NSC 639966) on a Loading Dose/Maintenance Dose Schedule in Patients with Advanced Cancer

  2004cited by this paper
• Efficient cancer therapy with a nanobody-based conjugate.

  2004cited by this paper
• Structure and function of the epidermal growth factor (EGF/ErbB) family of receptors.

  2004cited by this paper
• The interplay between Src and integrins in normal and tumor biology

  2004cited by this paper

• Design, Synthesis, Docking Studies, and Investigation of Dual EGFR/VEGFR‐2 Inhibitory Potentials of New Pyrazole and Pyrazolopyridine Derivatives

  2025cites this paper
• Disease-modifying strategies: Targeting protein kinases in multiple sclerosis and other autoimmune disorders.

  2025cites this paper
• Harnessing potential COX-2 engagement for boosting anticancer activity of substituted 2-mercapto-4(3H)-quinazolinones with promising EGFR/VEGFR-2 inhibitory activities.

  2024cites this paper
• Treatment of autoimmunity: The impact of disease-modifying therapies in multiple sclerosis and comorbid autoimmune disorders.

  2023cites this paper
• Protein kinases on carbon metabolism: potential targets for alternative chemotherapies against toxoplasmosis

  2023cites this paper
• Evolving strategies and application of proteins and peptide therapeutics in cancer treatment.

  2023cites this paper
• Novel pyrazole-based COX-2 inhibitors as potential anticancer agents: Design, synthesis, cytotoxic effect against resistant cancer cells, cell cycle arrest, apoptosis induction and dual EGFR/Topo-1 inhibition.

  2022cites this paper
• A Novel ERK2 Degrader Z734 Induces Apoptosis of MCF–7 Cells via the HERC3/p53 Signaling Pathway

  2022cites this paper
• Safety, pharmacokinetics, and preliminary efficacy of E6201 in patients with advanced solid tumours, including melanoma: results of a phase 1 study

  2018cites this paper
• Drug design of Src Kinase inhibitor : An overview

  2018cites this paper
• Direct Estimation of Differences in Causal Graphs

  2018cites this paper
• Pyrrolopyrimidine, A Multifaceted Scaffold in Cancer Targeted Therapy

  2018cites this paper
• Drug Targeting and Delivery

  2017cites this paper
• HIPPO-Integrin-linked Kinase Cross-Talk Controls Self-Sustaining Proliferation and Survival in Pulmonary Hypertension.

  2016cites this paper
• Redox mechanism, spectrophotometrical characterisation and voltammetric determination in serum samples of kinases inhibitor and anticancer drug dasatinib

  2015cites this paper
• Unravelling Drug Resistance Mechanisms in Breast Cancer

  2015cites this paper
• Design, synthesis and biological evaluation of type-II VEGFR-2 inhibitors based on quinoxaline scaffold.

  2014cites this paper
• Hsp27 as a therapeutic target in cancers.

  2014cites this paper
• Protein mislocalization: mechanisms, functions and clinical applications in cancer.

  2014cites this paper
• Boolean ErbB network reconstructions and perturbation simulations reveal individual drug response in different breast cancer cell lines

  2014cites this paper
• [Protein tyrosine kinase inhibitors in cancer therapy].

  2012cites this paper
• Clinical development of 2NME-based oncology treatment regimens.

  2011cites this paper
• Mitogen-Activated Protein Kinase-Activated Protein Kinases and Metastasis

  2010cites this paper
• Heat shock protein 27 phosphorylation: kinases, phosphatases, functions and pathology

  2009cites this paper
• Relations between the mitogen-activated protein kinase and the cAMP-dependent protein kinase pathways: comradeship and hostility.

  2008cites this paper
• β‐catenin mediates alteration in cell proliferation, motility and invasion of prostate cancer cells by differential expression of E‐cadherin and protein kinase D1

  2008cites this paper
• γ-Glutamyltransferase is upregulated after oxidative stress through the Ras signal transduction pathway in rat colon carcinoma cells

  2007cites this paper
• In vivo functions of mitogen-activated protein kinases: conclusions from knock-in and knock-out mice

  2007cites this paper
• Gamma-glutamyltransferase is upregulated after oxidative stress through the Ras signal transduction pathway in rat colon carcinoma cells.

  2007cites this paper
• A perspective on tyrosine kinase inhibitors in gastrointestinal stromal tumors and cancer: past and present with emphasis on future and cost

  2007cites this paper
• Novel Small-Molecule Inhibitors of Src Kinase for Cancer Therapy

  2007cites this paper
• Medicinal Chemistry Research Design, Synthesis and Biological Evaluation of Novel Thiophene and Theinopyrimidine Derivatives as Anticancer Agents

  year unknowncites this paper